| Issue Date | Title | Author(s) |
| 2014-01-01 | Across the pulmonary epithelial barrier: Integration of physicochemical properties and human cell models to study pulmonary drug formulations | Haghi, M; Ong, HX; Traini, D; Young, P |
| 2011-01 | Cellular release profiling of controlled release dry powder pulmonary formulation | Ong, HX; Traini, D; Bebawy, M; Young, P; Dalby, RN; Byron, PR; Peart, J; Suman, JD; Young, PM |
| 2015-06-01 | CHARACTERIZATION OF A COMMERCIAL NASAL POWDER DRUG DELIVERY DEVICE | Pozzoli, M; Sonvico, F; Zhu, B; Rogueda, P; Traini, D; Young, P |
| 2010-01 | Characterization of P-gp Expression and Function vs. Time and Passage in the Calu-3 Air-Interface Model for Drug Delivery to the Lung | Haghi, M; Young, P; Traini, D; Bebawy, M; Dalby, RN; Byron, PR; Peart, J; Suman, JD; Farr, SJ; Young, PM |
| 2011-01 | Comparison of albuterol sulphate and base dry powder particulate deposition using the Calu-3 lung epithelial model | Haghi, M; Traini, D; Bebawy, M; Young, P; Dalby, RN; Byron, PR; Peart, J; Suman, JD; Young, PM |
| 2019-01-01 | Euler–Lagrange approach to investigate respiratory anatomical shape effects on aerosol particle transport and deposition | Islam, MS; Saha, SC; Sauret, E; Ong, H; Young, P; Gu, YT |
| 2013-08-01 | Multiple dosing of simvastatin inhibits airway mucus production of epithelial cells: Implications in the treatment of chronic obstructive airway pathologies | Marin, L; Traini, D; Bebawy, M; Colombo, P; Buttini, F; Haghi, M; Ong, HX; Young, P |
| 2014-01 | Optimization of RPMI 2650 Cells as a Model for Nasal Mucosa | Pozzoli, M; Sonvico, F; Ong, HX; Traini, D; Bebawy, M; Young, P; Dalby, RN; Byron, PR; Peart, J; Suman, JD; Farr, SJ; Young, PM; Traini, D |
| 2019-01-01 | Saturated fatty acids, obesity, and the nucleotide oligomerization domain–like receptor protein 3 (NLRP3) inflammasome in asthmatic patients | Wood, LG; Li, Q; Scott, HA; Rutting, S; Berthon, BS; Gibson, PG; Hansbro, PM; Williams, E; Horvat, J; Simpson, JL; Young, P; Oliver, BG; Baines, KJ |
